Assessment of Serum Leptin in Vitiligo Patients

Status Not yet recruiting

Clinical Trial Summary

Evaluation of serum leptin in vitiligo patients and control Assessing its correlation to the body mass index and disease dermographic data .

Clinical Trial Description

, leptin is supposed to contribute to vitiligo pathogenesis through promoting the release of pro-inflammatory mediators such as tumor necrosis factor α "TNF," IL-2 and IL-6, as well as enhancing cytotoxic T cells "CD8" recruitment and inhibiting the functions of regulatory T cells "Tregs". Leptin can also aid in induction of oxidative stress by activating nicotinamide adenine dinucleotide phosphate (NADPH) oxidase• Venous blood samples will be taken from patients and controls to evaluate serum leptin: Morning samples will be taken after 12-h overnight fast in plain vacutainer tubes and directly centrifuged (1098 g for 15 min). - Sera will be then collected in plain, capped, 5 ml centrifuge tubes "Eppendorf" and freezed at -20ᵒC in a well-monitored freezer until the analysis is performed• Serum leptin will be quantitatively assessed in vitro using DRG leptin Sandwich Enzyme Linked Immuno-Sorbent Assay "ELISA". - ELISA will be performed according to manufacturer's guidelines where each run included a standard curve. - Using the mean absorbance value for each sample, the corresponding concentration from the standard curve will be determined. ;

Study Design

Related Conditions & MeSH terms

Vitiligo

Clinical Trial Details

NCT number	NCT05549869
Study type	Interventional
Source	Sohag University
Contact	doaa z amin, resident
Phone	01019096561
Email	doaa_zaghloul_post@med.sohag.edu.eg
Status	Not yet recruiting
Phase	N/A
Start date	November 2022
Completion date	September 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05298033` - Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo	Phase 2
Recruiting	`NCT05872477` - Promoting Repigmentation After Epidermal Cell Suspension Grafting and preVENTing the Loss of Melanocytes Using Topical Ruxolitinib for Vitiligo in Resistant Areas	Phase 2
Terminated	`NCT04374435` - Evaluating the Efficacy of the Melanocyte Keratinocyte Transplantation Procedure in the Treatment of Vitiligo	N/A
Completed	`NCT04103060` - Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With Vitiligo	Phase 2
Terminated	`NCT04271501` - Feasibility Study to Evaluate RECELL and Melanocyte Keratinocyte Transplantation Procedure for Repigmentation of Stable Vitiligo Lesions	N/A
Completed	`NCT04530344` - Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo	Phase 3
Not yet recruiting	`NCT05008887` - Fractional CO2 Laser-assisted Cutaneous Delivery of Methotrexate Versus 5-fluorouracil in Stable Non-segmental Vitiligo	Phase 4
Terminated	`NCT02191748` - Assessing the Efficacy of Needling With or Without Corticosteroids in the Repigmentation of Vitiligo	Phase 2/Phase 3
Terminated	`NCT01262547` - A New Micrografting Technique for Vitiligo	Phase 2
Completed	`NCT01382589` - Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo	Phase 2
Active, not recruiting	`NCT04971200` - Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo	Early Phase 1
Completed	`NCT04872257` - Oral Vitamin D Supplementation Combined With Phototherapy as a Treatment for Vitiligo	N/A
Completed	`NCT04547998` - Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo Lesions	N/A
Not yet recruiting	`NCT04039451` - Prevalence of Psoriasis and Vitiligo in Assiut Governorate, Egypt
Not yet recruiting	`NCT03611348` - Microneedling and Latanoprost in Acrofacial Vitiligo	Phase 2/Phase 3
Recruiting	`NCT03199664` - Effectiveness of Narrow-band Ultraviolet B Combined With Topical Tacrolimus 0.03% in Treatment of Patients With Vitiligo	Phase 4
Recruiting	`NCT03340155` - Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases	N/A
Completed	`NCT03249064` - Response to Tregs in Innate Immunity Receptor LRP1 (CD91) and Tregs in Periferic Blood Mononuclear Cells in Patients With Non-segmentary Vitiligo	N/A
Recruiting	`NCT05635266` - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Recruiting	`NCT04246372` - Tofacitinib for Immune Skin Conditions in Down Syndrome	Phase 2